论文部分内容阅读
目的研究评价依达拉奉联合氯吡格雷治疗急性脑梗死的疗效及安全性。方法 98例急性脑梗死患者作为研究对象,随机分为对照组和实验组,各49例。对照组患者采用氯吡格雷治疗;实验组患者采用依达拉奉联合氯吡格雷治疗,对比两组患者的神经功能、临床疗效、不良反应发生率。结果实验组神经功能评分为(1.5±1.1)分,低于对照组的(3.8±1.2)分(P<0.05);实验组治疗总有效率(95.9%)高于对照组(79.6%)(P<0.05);实验组不良反应发生率(6.1%)低于对照组(26.5%),差异有统计学意义(P<0.05)。结论在急性脑梗死的临床治疗中应用依达拉奉联合氯吡格雷治疗,具有显著的临床疗效,在降低患者神经功能损伤的同时减少不良反应发生率,值得临床进行推广。
Objective To evaluate the efficacy and safety of edaravone plus clopidogrel in the treatment of acute cerebral infarction. Methods A total of 98 patients with acute cerebral infarction were randomly divided into control group and experimental group, with 49 cases in each. The patients in the control group were treated with clopidogrel. The patients in the experimental group were treated with edaravone plus clopidogrel, and the neurological function, clinical efficacy and incidence of adverse reactions were compared between the two groups. Results The neurological score of the experimental group was (1.5 ± 1.1) points lower than that of the control group (3.8 ± 1.2) (P <0.05). The total effective rate (95.9%) in the experimental group was significantly higher than that of the control group (79.6%) (P <0.05). The incidence of adverse reactions in the experimental group (6.1%) was lower than that in the control group (26.5%), the difference was statistically significant (P <0.05). Conclusions The application of edaravone and clopidogrel in the clinical treatment of acute cerebral infarction has significant clinical curative effect. It can reduce the incidence of adverse reactions in patients with neurological injury and deserve clinical promotion.